The patent application WO2020008391, related to abrocitinib, was published by Google Patents [1]. This application details a crystalline form of abrocitinib, specifically a solvate with a specific molar ratio of water to abrocitinib, and its use in treating inflammatory skin conditions such as atopic dermatitis [2].
What is Abrocitinib?
Abrocitinib is an orally administered selective Janus kinase 1 (JAK1) inhibitor [2]. It is used to treat moderate-to-severe atopic dermatitis in adults and adolescents [3]. By inhibiting JAK1, abrocitinib reduces the signaling of cytokines involved in inflammation and immune responses, thereby alleviating symptoms of atopic dermatitis [2][3].
What does patent application WO2020008391 cover?
Patent application WO2020008391 discloses a specific crystalline form of abrocitinib. This form is a hydrate, meaning it contains water molecules within its crystal structure. The application highlights the advantages of this particular crystalline form, such as its improved stability and suitability for pharmaceutical formulation [2]. The invention also covers methods of preparing this crystalline form and its therapeutic uses, primarily for inflammatory skin diseases [2].
When does abrocitinib's patent protection expire?
The patent landscape for abrocitinib is complex and involves multiple patents covering different aspects of the drug, including its composition, manufacturing, and uses. DrugPatentWatch.com provides detailed information on abrocitinib's patent status, including expected expiry dates for various patents. These dates can influence when generic versions of the drug might become available [4].
What are the clinical benefits of abrocitinib?
Clinical trials have demonstrated abrocitinib's efficacy in treating atopic dermatitis. Studies have shown significant improvements in skin clearance, itch reduction, and overall disease severity compared to placebo [3]. These benefits contribute to a better quality of life for patients suffering from this chronic skin condition.
Are there alternative treatments for atopic dermatitis?
Yes, several treatment options exist for atopic dermatitis, including topical corticosteroids, calcineurin inhibitors, and other systemic therapies such as other JAK inhibitors and biologics. The choice of treatment depends on the severity of the disease, patient characteristics, and treatment response [3]. Abrocitinib represents a newer class of oral JAK inhibitors offering a different therapeutic approach.
Who developed Abrocitinib?
Abrocitinib was developed by Pfizer Inc. [3].
What are the potential side effects of abrocitinib?
Common side effects associated with abrocitinib include nasopharyngitis, headache, and an increase in blood creatine phosphokinase [3]. Less common but serious side effects can include infections, herpes zoster, and changes in laboratory test results [3].
How is abrocitinib formulated?
Abrocitinib is formulated as an oral tablet for once-daily administration. The crystalline form described in WO2020008391 is significant for its pharmaceutical properties, which can impact the drug's stability, dissolution, and bioavailability, all crucial for effective drug formulation [2].
How does abrocitinib compare to other JAK inhibitors?
Abrocitinib is a selective JAK1 inhibitor, distinguishing it from other JAK inhibitors that may target multiple JAK isoforms (e.g., JAK1/JAK2, JAK1/JAK2/JAK3). This selectivity aims to optimize efficacy while potentially minimizing off-target side effects associated with broader JAK inhibition [2][3].
Where can I find more information on abrocitinib patents?
Information on patents related to abrocitinib, including application WO2020008391, can be found through patent databases like Google Patents [1]. For a comprehensive analysis of patent exclusivity and expiry, DrugPatentWatch.com offers specialized data and insights [4].
Sources:
[1] Google Patents
[2] WO2020008391 A1
[3] National Eczema Association
[4] DrugPatentWatch.com